Luxoft Holding, Inc Files Registration Statement for Proposed Initial Public Offering

TORTOLA, British Virgin Islands - Thursday, May 23rd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Luxoft Holding, Inc, a subsidiary of IBS Group Holding Limited, has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its Class A ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined. Luxoft has applied to have its Class A ordinary shares quoted on the New York Stock Exchange under the ticker symbol “LXFT”.

UBS Limited, Credit Suisse Securities (USA) LLC, J.P. Morgan Securities LLC, VTB Capital plc and Cowen and Company, LLC are the joint bookrunning managers for the proposed offering. A copy of the preliminary prospectus related to the offering may be obtained when available from UBS Securities LLC, by telephone at 1-888-827-7275 or by mail at Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171; from Credit Suisse Securities (USA) LLC, by telephone at 1-800-221-1037, by mail at Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by email at newyork.prospectus@credit-suisse.com; from J.P. Morgan Securities LLC, by telephone at 1-866-803-9204 or by mail at Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; from VTB Capital plc by telephone at +1 646-527-6313 or by mail at 452 Fifth Avenue, 23rd Floor, New York NY 10018; or from Cowen and Company, LLC, by telephone at 1-631-274-2806 or by mail at Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717.

A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Luxoft

Luxoft is a leading provider of software development services and innovative IT solutions to a global client base consisting primarily of large, multinational corporations. Luxoft’s services consist of core and mission critical software development and support, product engineering and testing, and technology consulting. Luxoft’s solutions are based on its proprietary products and platforms that directly impact clients’ business outcomes and efficiently deliver continuous innovation.

Contacts

Investor Relations:

Luxoft

Alina V. Plaia, +1-212-964-9900 ext.2404

Head of External Communications

 

KCI Launches Prevena™ Peel & Place™ Dressing with V.A.C.® Therapy Connector

Benefits of surgical incision management now available to more patients

SAN ANTONIO - Thursday, May 23rd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Kinetic Concepts, Inc. today launched a Prevena™ Peel & Place™ Dressing with a V.A.C.® Connector, which expands the availability of the Prevena™ Incision Management System. Now more patients will be able to benefit from surgical incision protection in facilities currently utilizing KCI V.A.C.® Therapy Systems. Surgeons will also have the flexibility to actively manage incisions with a variety of KCI therapy systems and dressing configurations to deliver the optimum patient outcome.

“We’ve been asking KCI for a connector that makes the Prevena™ Peel & Place™ Dressings compatible with its other V.A.C.® Therapy units and they have provided it,” said Professor Franco Bassetto, Full Professor of Plastic Surgery, University Hospital of Padova, Italy. “The Prevena™ System covers and protects the incision site and removes exudate and infectious material, which could save hospitals money by helping manage incisions in patients undergoing a variety of orthopedic, gynecological, cardiovascular and plastic surgery surgical procedures.”

The Prevena™ Incision Management System is the first and only powered negative pressure product designed specifically for surgical incision management. The Prevena™ System has been associated with a reduced risk of post-operative complications when compared to standard of care incision management in published studies covering a variety of incision types, including standard orthopedic, cardiothoracic and vascular procedures.

Two recently published independent studies on the Prevena™ System demonstrated favorable clinical outcomes in patients at risk for post-operative complications. This month, in the Journal of Thoracic and Cardiovascular Surgery, Dr. Grauhan, et al reported statistically significant results of a prospective controlled trial of 150 obese patients undergoing sternotomy procedures.1 In the study, the control group treated with conventional sterile wound dressings experienced a 16% rate of infection versus 4% in the group treated with Prevena™ Therapy (p=0.0266). In the United States, the average cost of a sternal wound infection is $64,000.2

Similarly positive results were reported in the March edition of the Journal of Vascular Surgery. Dr. Matatov, et al performed a retrospective analysis of 115 groin incisions in patients requiring femoral cut-down procedures for vascular surgery.3 In this study, 30% of the patients in the control group (treated with either skin adhesives or absorbent dressings) experienced wound infections, while only 6% of the group treated with Prevena™ Therapy developed wound infections (p=0.0011). Surgical Site Infections (SSIs) of the groin can increase hospital stay by more than 9 days, costing facilities more than $20,000 per infection to treat; they also have an adverse impact on patient quality of life.

"The Prevena™ Peel & Place™ Dressing with a connector makes active incision management available to more patients by using the V.A.C.® Therapy Units many hospitals already have in place,” said Joe Woody, president & CEO, KCI. “This allows surgeons to decide whether their mobile patients need a complete Prevena™ System, perhaps for homecare, or whether hospital-based patients would benefit from a few days of Prevena™ Therapy delivered via a traditional V.A.C.® Therapy Unit.”

KCI estimates more than three million procedures are performed each year worldwide that could benefit from incision management with the Prevena™ System.

For more information about KCI and the Prevena™ Incision Management System, please visit www.KCI1.com.

About KCI

Kinetic Concepts, Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 25 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively impacting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at www.KCI1.com.

1 Grauhan O, Navasardyan A, Hofmann M, Müller P, Stein J, Hetzer R. Prevention of poststernotomy wound infections in obese patients by negative pressure wound therapy. J Thorac Cardiovasc Surg. 2013 May;145(5):1387-92.

2Market Research National Level Report. Data from the Marketscan Projected Inpatient, Hospital Drug and Medpar Databases: Calendar Year 2011. New York, NY: Thomson Reuters; 2013

3Matatov T, Reddy KN, Doucet LD, Zhao CX, Zhang WW. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg. 2013 Mar;57(3):791-5.

Contacts

KCI Corporate Communications

Mike Barger, 210-255-6824

mike.barger@kci1.com

Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease Progression

ORLANDO, Fla - Wednesday, May 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter, randomized, controlled clinical trial show that endoscopic ablation therapy using the Barrx™ RF Ablation System is effective at eliminating Barrett’s esophagus, a pre-cancerous condition of the esophagus, and preventing disease progression.

The SURF Trial* (SUrveillance vs. RadioFrequency ablation) included 136 patients with Barrett’s esophagus containing confirmed low-grade dysplasia. Upon enrollment, patients were randomly assigned to receive either endoscopic ablation therapy and subsequent endoscopic observation (treatment group) or endoscopic observation alone (control group). Tissue samples (biopsies) were obtained at regular intervals after enrollment to assess for the presence of Barrett’s tissue, dysplasia and esophageal cancer.

The primary endpoint of the trial was a comparison of the risk of disease progression over time between the ablation and control groups. Disease progression was defined as the development of either high-grade dysplasia or esophageal cancer during follow-up. The authors reported that endoscopic ablation therapy resulted in a 94% relative risk reduction in disease progression, compared to controls (1.5% progression in ablation group vs. 25.0% progression in control group) over a two-year follow-up period.

Other endpoints included resolution of Barrett’s tissue and occurrence of adverse events. At last endoscopy visit, 90% of patients treated with ablation were free of all signs of Barrett’s esophagus tissue, while none of the patients in the control group demonstrated resolution of Barrett’s tissue. The most common adverse event was esophageal narrowing in the ablation group, which occurred in 7 patients (10.3%) and was resolved with endoscopic dilation.

“In patients with Barrett’s esophagus containing confirmed low-grade dysplasia, endoscopic ablation significantly reduced disease progression to high-grade dysplasia and esophageal cancer, as compared to surveillance alone,” said principal investigator Jacques Bergman, M.D., Ph.D., Professor of Gastrointestinal Endoscopy, Director of Endoscopy, Academic Medical Center, Amsterdam, the Netherlands. “The difference in the disease progression outcome between the two groups was so large, in fact, that the data safety monitoring board overseeing the trial recommended early stoppage of the trial, and patients in the control group will now be offered endoscopic ablation.”

The study, entitled “Radiofrequency Ablation in Barrett’s Esophagus with Confirmed Low-Grade Dysplasia: Results of a European Multicenter Randomized Controlled Trial (SURF),” was conducted at nine European medical centers with expertise in the management of Barrett’s esophagus, dysplasia and cancer. Dr. Bergman’s colleague, Kai Yi N. Phoa, M.D., presented the outcomes data yesterday (Abstract #1004) at Digestive Disease Week 2013, part of an American Gastroenterological Association research forum held here this week.

“This trial adds very important new information to the management algorithm for patients with Barrett’s esophagus containing confirmed low-grade dysplasia,” commented David S. Utley, M.D., Chief Medical Officer, Covidien GI Solutions. “Until now, there was some level of uncertainty regarding the optimal management strategy for a patient with low-grade dysplasia. We believe that this randomized, controlled trial provides the highest level of evidence that disease progression in this population is high over two years when observation alone is employed, and that this progression risk can be significantly reduced if the patient is treated proactively with endoscopic ablation.”

Barrett’s esophagus develops as a result of chronic injury from gastroesophageal reflux disease. The normal esophageal lining is replaced with abnormal cells (Barrett’s tissue), predisposing the patient to a risk for developing adenocarcinoma (cancer) of the esophagus. Patients with Barrett’s who ultimately develop cancer typically do so through a series of steps, starting with early Barrett’s, proceeding to low-grade dysplasia or high-grade dysplasia and then, finally, progressing to cancer.

*The SURF Trial was supported by funds, products and collaboration provided by Covidien.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Contacts

Covidien

John Jordan, 508-452-4891

Manager, Communications

Surgical Solutions

john.jordan@covidien.com



Coleman Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com



Marguerite Copel, 203-821-4720

Vice President, Communications

Surgical Solutions

marguerite.copel@covidien.com



Todd Carpenter, 508-452-4363

Senior Director

Investor Relations

todd.carpenter@covidien.com

Gemalto Integrates Qualcomm Technology to Enable Rapid and Cost Effective Design and Deployment of M2M Solutions

LAS VEGAS - Wednesday, May 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Regulatory News:

CTIA Wireless - Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, will add a new module based on the Qualcomm Technologies, Inc. QSC 6270-Turbo chipset to its Cinterion® portfolio of cellular modules and devices. With support for Java™(1) and for the SensorLogic cloud-based software as a service (SaaS) platform, the new device enables Gemalto to launch the next generation of embedded solutions and services that simplify Machine-to-Machine (M2M) technology deployment and speed up customized applications development. The Cinterion® M2M end-to-end solution portfolio provides secure wireless connectivity for a variety of applications including automotive telematics, tracking & tracing, alarm systems and mHealth.

The Cinterion® modules utilize the application processor power to host customers’ application software directly onboard the module, eliminating the expense of additional processing and memory chips, thereby reducing overall cost, complexity and space. Multiple applications can run in parallel and the rich application environment allows the vast Java global developer community to reuse existing resources and to speed up the complete system integration. The architecture also simplifies over-the-air (OTA) provisioning and remote updating, to distantly manage M2M applications that often remain in the field for more than 10 years. Cinterion® modules and solutions are seamlessly integrated with the SensorLogic application enablement platform, which permits to quickly transform all sorts of devices into manageable assets that optimize business performance.

From medical devices, automobiles and smart meters to shipping containers and alarm systems, more and more products are equipped with sensors that are together collecting massive amounts of data. Currently, most of this data remains siloed. And the vast majority of embedded software development is still customized for each specific device, leading to slow development cycles and interoperability issues. The complete Gemalto M2M’s Edge to Enterprise offering, including the Cinterion® SensorLogic cloud-based software as a service (SaaS) platform allows to seamlessly integrate the big data from the edge of the network into existing processes of any kind.

“When we integrated Oracle Java onto the QSC6270-Turbo chipset, we wanted to enable the worldwide Java development community to imagine, develop and deploy cellular-based M2M applications,” said Nakul Duggal, Vice President of Product Management at Qualcomm Technologies, Inc. “We are pleased that Gemalto shares our vision for the Internet of Everything and has now added the Java-enabled QSC6270-Turbo to their complete range of solutions utilizing Qualcomm Technologies, Inc. technologies that it offers to the ecosystem.”

“By aligning a family of powerful M2M products supporting both Java and SensorLogic, we give customers superior tools for designing, deploying and managing the lifecycle of M2M solutions, for healthcare, logistics, automotive, smart energy and any industry currently struggling with the integration of big data,” said Andreas Haegele, Head of the M2M Product Portfolio at Gemalto. “We launched an industry innovation in 2003 when we first added Java to our Cinterion M2M modules, and we’re excited about extending the capability of our Qualcomm based module family to offer a mass market 3G solution to enhance business mobility and security in M2M.”

Visit Gemalto CTIA booth #5625 to see a Java-based mHealth demonstration.

1 Oracle Java ME Embedded integrated in the QSC6270-Turbo chipset from Qualcomm Technologies Inc. ' enables software to be delivered via modules and in-market upgrades, allowing device manufacturers to extend the lifetime, flexibility and value of embedded solutions.

Qualcomm Technologies, Inc. is a wholly owned subsidiary of Qualcomm Incorporated.

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the world leader in digital security with 2012 annual revenues of €2.2 billion and more than 10,000 employees operating out of 83 offices and 13 Research & Development centers, located in 43 countries.

We are at the heart of the rapidly evolving digital society. Billions of people worldwide increasingly want the freedom to communicate, travel, shop, bank, entertain and work – anytime, everywhere – in ways that are enjoyable and safe. Gemalto delivers on their expanding needs for personal mobile services, payment security, authenticated cloud access, identity and privacy protection, eHealthcare and eGovernment efficiency, convenient ticketing and dependable machine-to-machine (M2M) applications. We develop secure embedded software and secure products which we design and personalize. Our platforms and services manage these products, the confidential data they contain and the trusted end-user services made possible.

Our innovations enable our clients to offer trusted and convenient digital services to billions of individuals. Gemalto thrives with the growing number of people using its solutions to interact with the digital and wireless world.

For more information visit www.gemalto.com, www.justaskgemalto.com, blog.gemalto.com, or follow @gemalto on Twitter.

Contacts

Gemalto

Media

Peggy Edoire, +33 4 42 36 45 40

Europe, Middle East & Africa

peggy.edoire@gemalto.com



Pierre Lelievre, +65 6317 3802

Asia Pacific

pierre.lelievre@gemalto.com



Nicole Smith, +1 512 758 8921

North America

nicole.smith@gemalto.com



Ernesto Haikewitsch, +55 11 5105 9220

Latin America

ernesto.haikewitsch@gemalto.com

Alison Kay appointed to lead Global Power & Utilities at Ernst & Young

LONDON - Wednesday, May 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Ernst & Young has announced the appointment of Alison Kay as the new Global Sector Leader for Power & Utilities, effective as of 1 July 2013. Alison will lead a global team of 3,600 professionals with extensive technical experience in providing assurance, tax, transaction and advisory services to the power and utilities sector.

Alison joined Ernst & Young in 2007 to lead the Advisory team for the utilities sector in the UK before becoming a member of the UK and Ireland Board in 2010. She has worked extensively with clients from across the sector globally, developing strong relationships with many of the most important leaders in the industry along the way.

A graduate from the University of Sheffield in the UK, Alison began her career with a successful four year period in industry, completing a MBA at the Manchester Business School in the process. She then spent several years at Accenture, consulting for power and utilities clients on generation, transmission and retail issues across Europe, before moving to Ernst & Young.

Commenting on her new role, Alison says: “In a world of uncertainty, changing regulatory frameworks and environmental challenges, power and utility companies need to respond and adapt while providing an affordable and secure energy supply locally. Ernst & Young has a truly global footprint in power and utilities and this new role provides an exciting opportunity to work with our teams across the world in developing solutions for our clients to address these significant industry challenges.”

Steve Almassy, Ernst & Young’s Global Vice Chair, Office of the Chairman Accounts and Industry, adds: “I am really pleased to welcome Alison to this global leadership role in Power & Utilities. Alison’s extensive sector experience and leadership will build on the great work that has already been achieved under her predecessor Ben van Gils.”

-ends-

Notes to Editors

About Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, our 167,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit www.ey.com.

This news release has been issued by EYGM Limited, a member of the global Ernst & Young organization that also does not provide any services to clients.

Contacts

Ann Burton

Ernst & Young Global and EMEIA Media Relations

+44 (0) 20 7980 0552

Ann.Burton@uk.ey.com

EVault Names Brett Flinchum as Vice President of Worldwide Operations

Experienced Customer Service Executive Joins EVault to Manage Support, Services and Operations

SAN FRANCISCO - Wednesday, May 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- EVault, Inc., a Seagate Company (NASDAQ: STX), today announced the appointment of Brett Flinchum as vice president of worldwide operations. Flinchum, a seasoned business leader with more than 15 years of operations experience, will lead EVault’s worldwide operations department, which is responsible for business services, IT operations, technical support, customer and expert services.

“Brett brings the perfect blend of experience and vision to oversee our worldwide operations and take it to the next level,” said Terry Cunningham, president and general manager of EVault. “Over the course of his career he has excelled in building and streamlining high-performing customer service and operations teams, skills that will help EVault continue to deliver world-class service to our tens of thousands of customers across the globe.”

Prior to joining EVault, Flinchum was COO at MegaPath Corporation, formerly Covad Communications, where he headed the company’s critical operations from the startup stage to nearly $600 million in revenue and led the merger of the two companies in 2010. His tenure saw the creation and deployment of automated customer provisioning and support platforms that not only served as a competitive advantage for Covad, but also helped revolutionize the industry. Under Flinchum’s leadership, Covad won the 2006 NeuStar “Customer First” Award, given to NeuStar customers who successfully package and deliver telecommunication and IP services utilizing NeuStar services. Flinchum also brings to EVault his ability to find innovative ways to optimize data center costs while delivering value added services that customers desire.

The hiring of Flinchum coincides with the unveiling of EVault’s customer experience management (CEM) vision, which will streamline customer touchpoints and deliver satisfaction across the entire spectrum of interactions between EVault and its 43,000 customers. To drive this transformation, EVault has created a new CEM group, designed to deliver the best customer experience in the market, and a new operations department headed by Flinchum and tasked with ensuring EVault delivers on the promise of CEM.

“Customer delight should be the core concentration of any business. As a leading provider of managed services, EVault has always placed a strong emphasis on its customer relations, which is something I’ve noticed and admired from afar,” said Flinchum. “I see significant opportunities for us to bolster EVault’s already strong customer relationships and processes as we continue to establish ourselves as one of the leading cloud software providers in the world.”

About EVault

More than 43,000 companies rely on EVault cloud-connected backup and recovery services. Delivered by a team of data recovery experts and using the very best cloud-connected technology, EVault backup solutions seamlessly integrate on-premise and online backup data protection for fast, local data access and ensured cloud disaster recovery. Optimized for distributed environments and backed by an ironclad cloud, EVault technology also powers the offerings of cloud services providers, data centers, telcos, ISVs, and many others. EVault is a Seagate Company.

Follow @EVault on Twitter and on Google+, subscribe to the blog and like EVault on Facebook.

Copyright 2013 EVault, Inc. All rights reserved. Seagate, Seagate Technology and the Wave logo are registered trademarks of Seagate Technology LLC in the United States and/or other countries. EVault and cloud-connected are either trademarks or registered trademarks of EVault, Inc., or one of its affiliated companies in the United States and/or other countries. All other trademarks or registered trademarks are the property of their respective owners.

Contacts

for EVault, Inc.

Darren Weiss, 1-415-625-8555

EVault@LaunchSquad.com

JPMorgan Chase Declares Common Stock Dividend and Reports on Preliminary Vote Results at Annual Meeting of Shareholders

NEW YORK--(BUSINESS WIRE)--The Board of Directors of JPMorgan Chase & Co. (NYSE:JPM) today declared a quarterly dividend of 38 cents per share on the outstanding shares of the corporation's common stock, an increase from the prior quarterly dividend of 30 cents per share. The dividend is payable on July 31, 2013, to stockholders of record at the close of business on July 5, 2013.

   At the annual meeting of shareholders held today, the Company announced preliminary results of the shareholder vote on five management proposals and four shareholder proposals. All of the management proposals were approved, including: the election of directors, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, approval of executive compensation, amendment to the Restated Certificate of Incorporation authorizing shareholder action by written consent, and reapproval of the Key Executive Performance Plan. None of the shareholder proposals were approved.

“We appreciate the support shown by shareholders and the thoughtful way many have engaged with us as they determined how to vote on these issues,” said Jamie Dimon, Chairman and CEO of JPMorgan Chase. “We take the feedback from shareholders very seriously and we will continue to build toward being best in class in corporate governance.”

Lee Raymond, Presiding Director of the Board said, “Our discussions with shareholders throughout this process have been constructive. The Board will continue to review its current structure and composition in light of today’s feedback and with the best interest of shareholders in mind.”

The shareholder vote numbers and percentages announced at the meeting are considered preliminary until the final results are tabulated and certified by independent inspectors of election. The final results will be reported on a Form 8-K that will be filed with the Securities and Exchange Commission later this week.

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $2.4 trillion and operations worldwide. The firm is a leader in investment banking, financial services for consumers, small business and commercial banking, financial transaction processing, asset management and private equity. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of consumers in the United States and many of the world's most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

Contacts

JPMorgan Chase & Co.
Investor:
Sarah Youngwood, 212-270-7325
Media:
Joseph Evangelisti, 212-270-7438